Cardiac Ischemia Clinical Trial
— CAST-HFOfficial title:
Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting
Verified date | November 2022 |
Source | Medical University Innsbruck |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomised, controlled clinical trial aims to evaluate the safety and efficacy of Cardiac Shockwave Therapy (CAST-HF) in patients with ischaemic heart failure requiring surgical revascularization. The main questions to answer are: - Does cardiac shockwave therapy, in addition to CABG surgery, improve left ventricular ejection fraction? - Is cardiac shockwave therapy in addition to CAGB surgery safe? Participants will be randomised into intervention (cardiac shockwave therapy) and control (sham treatment with an inactive applicator) groups.
Status | Completed |
Enrollment | 63 |
Est. completion date | March 15, 2023 |
Est. primary completion date | June 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 90 Years |
Eligibility | Inclusion criteria - Male or female patients between 21 and 90 years of age undergoing primary coronary artery bypass grafting - Presentation with reduced left ventricular function, defined as LVEF = 40% measured by cardiac MRI - Presentation with regional left ventricular wall motion abnormalities - Written informed consent from the patient for participation in the study Exclusion criteria - Significant concomitant aortic valve disease requiring surgical treatment (other than significant aortic valve disease not detected in preoperative cardiac ultrasound but detected during surgery) - Serious radiographic contrast allergy - Patient in cardiogenic shock or presenting with acute myocardial infarction (STEMI or NSTEMI) - Patient with a contraindication for cardiac MRI - History of significant ventricular arrhythmia, other than MI-associated arrhythmia - Comorbidity reducing life expectancy to less than one year - Presence of a ventricular thrombus - Presence of a cardiac tumour - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Innsbruck - Competence Center for Clinical Trials | Innsbruck | Tirol |
Lead Sponsor | Collaborator |
---|---|
Medical University Innsbruck |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy endpoint is the improvement in LVEF measured by cardiac MRI from baseline to 360 days. | The primary efficacy objective is to assess the efficacy of cardiac shock wave therapy in patients undergoing primary coronary artery bypass grafting and suffering from reduced left ventricular function = 40% | 360 days | |
Primary | The primary safety endpoint is the occurrence of device-related complications (adverse device effects or serious adverse device effects) within 360 days. | The primary safety objective is to assess the safety profile of the cardiac shock wave therapy device. | 360 days | |
Secondary | Secondary efficacy-related endpoints include patient-reported outcomes. | Change in:
6- Minute Walk Test Distance NYHA functional class Serum nt-proBNP levels Renal function (GFR) Seattle Angina Pectoris Questionnaire (SAQ) 36-item short-form survey (SF36) Minnesota Living with Heart Failure Questionnaire (MLHFQ) |
360 days | |
Secondary | Secondary safety-related endpoints include patient-reported outcomes. | Occurance of ventricular arrhythmia during hospital stay
Occurrence of device-related peri-operative myocardial damage detected by rise of cardiac biomarkers (CK-MB, TropT) Occurrence of signs of device-related infection (CRP, leucocytosis) during hospital stay |
6 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06154473 -
Assessment of Patients Undergoing Cardiac Surgery and Admitted to the Intensive Care Unit
|
||
Completed |
NCT03203057 -
Induced Myocardial Ischemia: a Serial Troponin T and Troponin I Measurements
|
N/A | |
Active, not recruiting |
NCT06235424 -
Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement
|
Phase 4 | |
Recruiting |
NCT04749212 -
Perioperative Troponin I and NT Pro-BNP in Lung Resection
|
||
Recruiting |
NCT03798652 -
Improved Prediction of Functional Recovery After Revascularisation Using Combined Assessment of Myocardial Ischaemia and Viability by CMR - Pilot Study
|
||
Recruiting |
NCT05726604 -
4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy
|
N/A | |
Completed |
NCT04458155 -
Li-Hep vs. Non-Li-Hep Coated Transfer Device
|
||
Not yet recruiting |
NCT06414330 -
Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery
|
N/A | |
Completed |
NCT02055443 -
Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain
|
N/A | |
Completed |
NCT03053128 -
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease
|
N/A | |
Completed |
NCT03433963 -
The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution
|
N/A | |
Recruiting |
NCT05757947 -
Study of the No-touch Saphenous Vein Graft
|
N/A | |
Completed |
NCT05164640 -
Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"
|
N/A | |
Completed |
NCT03642730 -
Interactive Guided Ultrasound Examinations Done by Non-experts of Ultrasound Imaging
|
N/A | |
Recruiting |
NCT05006183 -
Instantaneous Wave-free Ratio Guidance Strategy Evaluation in the Treatment of Multivessel Acute Coronary Syndrome.
|
N/A | |
Active, not recruiting |
NCT05453097 -
Prognostic Value of the Selvester QRS Score for Perioperative Myocardial Injury Following Non-cardiac Surgery
|
||
Recruiting |
NCT03800082 -
Development and Usability Testing of a Progressive WebApp for Women With Heart Disease
|
N/A | |
Completed |
NCT03857503 -
Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)
|